Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 14;2(1):vdaa051. doi: 10.1093/noajnl/vdaa051

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 5. — Marizomib (MRZ) suppresses atypical teratoid/thabdoid tumor (AT/RT) tumor growth in vivo. (A) Chymotrypsin-like activity of disaggregated single cells isolated from mouse cerebellums 1 h post-injection with either 200 µg/kg MRZ or an equivalent volume of vehicle. Statistics shown are for 1-way ANOVA, n = 8. (B, C) Kaplan–Meier graphs showing cerebellar xenografts of MAF-737A (B) or BT16 (C) cells, treated twice weekly with either 200 µg/kg (B) or 150 µg/kg (C) MRZ. (D) Dose–response curves to 5-day treatment from BT16 cells isolated from mice in the treatment group of (C). (E) Western blot analysis of tumors extracted from mice from (B), blotting for total and cleaved PARP, total and cleaved Caspase 3, and GAPDH loading control.